Case Report

Growth hormone as a rescue treatment in maple syrup urine disease with lessons from pediatric burn literature, case report and brief literature review

Brooke E. Kimbrell a,*, Faith Hicks b, Cortney B. Foster c, Omayma A. Kishk d, Sara A. Quinteros-Fernandez e, Maria Eleni Nikita f, Carol L. Greene g, h

a 1501 Kennewick Rd, Baltimore, MD 21218, United States of America
b Prisma Health Systems, Greenville, SC 29605, United States of America
c Division of Pediatric Critical Care, Department of Pediatrics, University of Maryland Medical Center, Baltimore, MD 21201, United States of America
d Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD 21218, United States of America
e Department of Nutrition, University of Maryland Medical Center, Baltimore, MD 21201, United States of America
f Division of Pediatric Endocrinology, Department of Pediatrics, University of Maryland Medical Center, Baltimore, MD 21201, United States of America
g Division of Genetics, Department of Pediatrics, University of Maryland Medical Center, Baltimore, MD 21201, United States of America
h Department of OB GYN and Reproductive Services, University of Maryland Medical Center, Baltimore, MD 21218, United States of America

* Corresponding author at: Kennedy Kreiger Institute, 707 North Broadway, Baltimore MD 21205, United States of America
E-mail addresses: bekimbrell@gmail.com, kimbrell@kennedykrieger.org (B.E. Kimbrell), Faith.hicks@prismahealth.org (F. Hicks), Cfoster@som.umaryland.edu (C.B. Foster), saraquinteros@um.edu (S.A. Quinteros-Fernandez), mnikita@som.umaryland.edu (M.E. Nikita), carol.greene@som.umaryland.edu (C.L. Greene).

https://doi.org/10.1016/j.ymgmr.2020.100685
Received 17 November 2020; Accepted 18 November 2020

ABSTRACT

Maple Syrup Urine Disease (MSUD) is a rare inherited disorder of branched chain amino acid metabolism characterized by cerebral edema and death in uncorrected metabolic crisis. It is conventionally treated with intensive nutritional therapy to prevent and correct metabolic crisis. This paper reports the use of growth hormone as a pharmacologic rescue agent in the case of an 11-year-old male with MSUD and metabolic crisis refractory to standard interventions. The initiation of short courses of growth hormone correlated with corrected mental status, resolution of metabolic acidosis, and improvement in plasma leucine levels on two occasions during an admission to the pediatric intensive care unit. This is the first known case report of the use of growth hormone in MSUD since contemporary dietary management became available. The discussion includes a literature review of the use of growth hormone in inherited diseases of amino acid metabolism and a brief discussion of protein anabolic pharmacotherapeutic agents shown to improve net protein balance in pediatric burn patients.

We propose that growth hormone and other protein anabolic agents may be valuable adjuvants to standard therapy in children with inherited metabolic disease.

ARTICLE INFO

Keywords:
Maple syrup urine disease
Growth hormone
Metabolic crisis
Inherited metabolic disease
Anabolic pharmacology
Branched-chain alpha-ketoacid dehydrogenase deficiency

1. Introduction

Maple Syrup Urine Disease is an inherited metabolic disorder of amino acid metabolism in caused by deficiency in branched chain ketoacid dehydrogenase enzyme leading to the accumulation of branched chain amino acids (BCAA) such as leucine, isoleucine, and valine. Untreated, the buildup of these acids leads to progressive metabolic ketoacidosis, encephalopathy, and cerebral edema. The condition is typically detected on metabolic newborn screen and is treated by limiting dietary intake of natural protein containing branched chain amino acids while providing adequate essential non branched chain amino acids via special medical food [1]. Metabolic crisis can be triggered by catabolic states releasing branched chain amino acids from skeletal muscles or by decreased natural protein tolerance due to physiologic stress. In individuals with MSUD, acute illness can lead to a metabolic crisis, cerebral edema, and irreversible neurologic injury. Although MSUD has been known for decades, it is a rare disease and only recently have guidelines for its management been published [2,3]. This report discusses a case in which a child’s metabolic crisis was not controlled by the strategies included in these guidelines. We report the use of growth hormone as an adjuvant therapy, which is referenced by older literature for MSUD [4] and some recent case series in other
inherited metabolic disorders [5-8] and is supported by recent research in pediatric burn patients [9].

The Nutritional Management Guidelines for Maple Syrup Urine Disease published in 2014 and guidelines published by Genetic Metabolic Di-
ettians International in 2013 provide recommendations for care of pa-
tients in metabolic crisis based around aggressive nutritional
management to promote anabolism including supplying up to 150% of
usual energy intake, BCAA free protein for 1–2 days, supplementation
of valine and isoleucine, and electrolytes. In addition to these nutritional
management strategies, seriously ill patients may need insulin infusion,
dialysis, hemofiltration, parenteral nutrition and/or tube feeding while
the source of the decompensation is addressed [2,3]. Protein anabolic
pharmacotherapy has potential to complement nutritional management
and ideally reduce the need for dialysis and other invasive interventions
during periods of metabolic stress. Because inherited metabolic disease
is rare, the literature on protein anabolic pharmacotherapy in this
population is limited [4,10]. However, the protein catabolic state of
severely burned children has been well documented, and several high-
quality studies have been performed on protein anabolic pharma-
terapy in that population [9]. This paper proposes that this body of
literature represents a valuable fund of knowledge which could be
applied to the care of children with inherited metabolic disease.

2. Case summary

KP is a 11-year-old Hispanic male with MSUD detected on newborn
metabolic screen and confirmed by blood amino acids with character-
estic elevations including allosoleucine and the absence of elevation of
glycine and alpha-ketoglutarate. DNA testing was offered and not pur-
sued after family decided that they would not attempt any future pregnancy. Biopsy for enzyme assay was not requested since amino acid levels clearly indicated classical MSUD. Because he had an early episode of sepsis and congenital nystagmus, we screened for congenital disorders of glycosylation by analysis of transferrin with normal results. Nystagmus gradually resolved after surgery for exotropia. Growth was normal, there were no dysmorphic features and development was typical for a child with MSUD with history of episodes of MSUD crisis; therefore, other diagnostic genetic or endocrine testing was undertaken.

He had two significant episodes of severe metabolic decompensation before age 7. One episode was complicated by significant cerebral paralysis were weaned. During airway interventions his branched chain amino acids were again decreased to 3.5 g daily given his high AA levels (leucine still >1100 nmol/mL). As his activity level increased on June 13th, his serum

| Table 1 |

| Anthropometrics prior to admission | Percentile | Z-score |
|----------------------------------|------------|---------|
| Weight                           | 38.2 kg    | 40th    | −0.25   |
| Height                           | 136 cm     | 4th     | −1.75   |
| BMI                              | 20.7       | 84th    | 0.98    |

Despite aggressive nutritional management, his amino acids trended
up and continuous insulin infusion and increased dextrose to 8 mg/kg/
min were started on June 8th to stimulate anabolism while he remained
immobilized. He was hemodynamically stable, required only continuous
airway pressure for respiratory support, and was without sign of end
organ dysfunction on laboratory monitoring. In the evening on June
11th his AA levels were found to be markedly elevated with leucine
1050 nmol/mL and he developed a metabolic acidosis to 7.23 with an
anion gap of 15 indicating a catabolic state (Fig. 1). He had altered
mental status with decreased ability to follow commands. Dialysis was
considered but would have been counterproductive overall given his
negative protein balance over the course of admission. After consulta-
tion with other metabolic genetics colleagues and review of the avail-
able case reports and short case series reporting the use of growth
hormone in children with inherited metabolic disease [4-8], a 3-day
course of growth hormone was started and his natural protein was
increased to 7 g to facilitate protein anabolism. No changes to respira-
tory support or infusions were made. Within 24 h he had normalizations
of his anion gap and metabolic acidosis, his ability to follow commands
improved, but his AA levels remained stably elevated. His first trach
change was completed the next day on June 12th and sedation and
paralysis were weaned. During airway interventions his branched chain

amino acid free formula was held for most of the day and natural protein
was again decreased to 3.5 g daily given his high AA levels (leucine still
>1100 nmol/mL). As his activity level increased on June 13th, his serum
branched chain amino acids began slowly down trending but leucine
remained close to 1000 despite continuous insulin infusion and optimization of nutritional management.

His BCAA levels began rising again on June 16th and he became lethargic on June 17th with a leucine level of 1322 nmol/mL. There was concern for possible infection as he had up-trending serum white blood cells and platelets, with red and white blood cells in his urine. Urine culture grew 25,000 Enterobacter cloacae, and he was treated with IV antibiotics. Serum ESR and CRP were elevated but overall down trending from his recent surgery. His renal ultrasound was normal and serum creatinine remained normal. Again, dialysis was discussed for treatment of metabolic crisis with altered mental status, but his mother did not consent. Continued literature search regarding protein anabolic pharmacotherapy options lead the authors to a body of literature reporting the use of growth hormone to treat the protein catabolic state of severely burned children with positive protein balance kinetics measured by radioisotope tracers [9]. A second course of growth hormone was started, this time for 7 days in conjunction with physical therapy as tolerated. BCAA levels stabilized then down trended sharply on June 19th to leucine 519 nmol/mL, isoleucine 70 nmol/mL, and valine 169 nmol/mL. His natural protein was increased to 7 g/day and his BCAA levels did not rise. He passed a modified barium swallow study and was transitioned back to his home MSUD formula orally with nasogastric (NG) supplementation. He was allowed to take solids foods with mom keeping a protein count with a goal of 7 g per day so that natural protein provision was transitioned from formula to solid food. Enteral formula was supplemented as needed to achieve protein goal for the day. Insulin and dextrose were weaned off. By the completion of his second course of growth hormone on June 24th, his AA levels had normalized and he was tolerating his home nutrition and supplement regimen. He had regained his admission weight and continued to gain weight along the 50-60th percentile. He required prolonged admission for tracheostomy training and physical rehabilitation.

After resolution of his metabolic crisis, he displayed increased natural protein tolerance and was discharged on 12 g/day of natural protein. His natural protein prescription was gradually decreased to 8 g/day over a twelve-month period with close monitoring of his serum amino acid levels and growth curves. This period of increased natural protein tolerance is attributed to correction of his hospital acquired muscle wasting as well as the onset of puberty. He is scheduled for a laryngoscopy for evaluation of laryngotracheal reconstruction. Parental informed consent was obtained for the publication of this case report.
3. Results and discussion

3.1. Discussion of nutritional management

Current pediatric critical care guidelines recommend estimating the Resting Energy Expenditure (REE) as using the Schofield equation without stress factors, in the absence of indirect calorimetry [11]. For KP, his REE is estimated at 1340 kcal/day, or 44 kcal/kg. Estimated protein needs during critical illness are at least 1.5 g/kg [12]. We initiated nutritional support immediately upon admission. He was transitioned from parental to enteral, then to oral nutrition while maintaining calorie provision from 150 to 200% of REE. The calories provided well exceeded typical provision for critical illness, and later, his ambulatory state. Non BCAAs were also provided in excess of the recommended need for pediatric critical illness. This intensive approach was taken for KP with the intent to reverse catabolism and promote anabolism, which would result in the reduction of plasma leucine. However, his leucine levels remained persistently elevated despite seamless provision of aggressive nutrition support. Table 2 compares the protein and energy provided to standard of care ranges in ambulatory and acute illness [11–12].

3.2. Discussion of response to growth hormone

This case demonstrates that growth hormone can be used as a rescue intervention when standard of care nutritional therapy and use of insulin are unable to reverse metabolic crisis. Use of growth hormone to treat metabolic crisis in maple syrup urine disease has been mentioned in medical literature as early as 1968 [4]. However, this is the first recent case report documenting the protein anabolic response to growth hormone in inherited metabolic disease. The administration of growth hormone during the first course was effective at correcting clinical signs of metabolic encephalopathy, resolving his acidosis, and stabilizing his plasma leucine levels. In contrast, the rapid decline in his plasma amino acid levels with the second course, even in the setting of increased natural protein intake, was attributed to the protein anabolic effects of growth hormone augmented by the physiologic stimulus of physical activity Figure 1.

3.3. Discussion of pharmacology and safety

There are no known studies on the most appropriate dose of growth hormone in metabolic crisis. In this case, we used the standard dose approved for the available manufacturer for prepubertal children, which is 0.3 mg/kg/week divided by 7 for a daily dose of 0.04 mg/kg/day [13]. This dose represented a large volume and eight subcutaneous injections daily because the concentration/product available for use on our hospital’s formulary. The product on formulary Genotropin MiniQuick® (somatropin) 0.2 mg injections. Several of the injections were able to be given while patient was still under sedation. By the time patient was off sedation, he only had a couple of days left of the somatropin, so the hospital was unable to purchase another somatropin product. The large number of injections may limit the feasibility of the use of this project in some clinical scenarios, but other products can be used to avoid this limitation.

There are no studies of the safety profile of growth hormone for short term use. The clinical practice guidelines for the use of growth hormone for growth hormone deficiency and idiopathic short stature discusses rare side effects of chronic administration. These rare side effects include: decreased insulin sensitivity, changes in cortisol metabolism which could theoretically unmask an undiagnosed adrenal insufficiency, theoretical increase risk of neoplasm in susceptible children, and problems associated with rapid linear growth including slipped capital femoral epiphysis (SCFE), increased scoliosis, and intracranial hypertension. The incidence of these adverse effects is reportedly <3% in children undergoing long term therapy and do not require specific surveillance [14]. Of these potential adverse reactions, decreased insulin sensitivity and altered cortisol metabolism would pose the greatest risk to a child in metabolic crisis. These effects have not been specifically studied or reported with acute administration of growth hormone.

The use of growth hormone in critically ill children has very limited evidence. Dysregulation of GH and insulin like growth factor 1 axis has been demonstrated in critically ill adults and children [15,16]. After the development of recombinant GH in the 1985, several studies in critically ill adults showed positive safety profiles and improvement in nitrogen balance [17]. However in 1999 a pair of prospective, double blind, randomized control trials of high dose growth hormone in adults with critical illness including surgery, trauma, and sepsis showed increased morbidity and mortality in the treatment group despite improved nitrogen balance [18]. The source of this increased mortality is unclear with some groups speculating that there may have been inadequate nutritional support, specifically glycine supplementation [17]. After this study, further exploration of GH in critical care settings has been limited. The Growth Hormone Research Society published a critical evaluation of the safety of recombinant GH administration in the Journal of Clinical Endocrinology and Metabolism in 2001. It states “Any GH treatment other than replacement in those who have GH deficiency should be considered as pharmacological. In specific conditions where pharmacological treatment with GH is being considered, standard safety data should be collected and protocols for new drug development followed. The detrimental outcome of high-dose GH treatment in intensive care patients cannot be extrapolated to other conditions, which may potentially benefit from GH treatment [19].”

3.4. Focused literature review

A literature search of pharmacologic effects of growth hormone on protein anabolism lead the author to a useful literature review by Diaz et al. discussing the catabolic state of burn victims and the effects of various pharmacologic agents on protein kinetics in severely burned children. We found this review to be relevant to our patient because it demonstrates the net protein anabolic effect of growth hormone. They report that growth hormone administered at 0.2 mg/kcal once daily for 19 days increased the net protein balance of treated children by 67% compared to controls. Our patient responded well to standard dosing approved for treating growth hormone deficiency, however it is worth noting that the dose reported in the burn literature is five times greater than the dose used in our patient. Diaz et al. also summarized results of

| Table 2 | Comparison of recommended and provided nutrition in ambulatory and acute illness settings. KP was consistently provided with energy and protein in excess of recommended guidelines to promote anabolism. |
|---|---|---|---|---|---|
| | Ambulatory goal in MSUD | Ambulatory goals for KP prior to admission | Recommendations for child in critical care | Recommendations for acutely ill ambulatory child | Provision during acute and critical illness for KP |
| Natural Protein (g/day) | 5–8 g/day | 7 g/day | Not applicable | Not applicable | 0–7 g/day |
| Total Protein (g/kg) | 1.2–1.8 g/kg | 1.5 g/kg | >1.5 g/kg | Not available | 2–3.5 g/kg |
| Energy (Kcal/kg) | 40–90 kcal/kg | 45–55 kcal/kg | 34 kcal/kg | 44 kcal/kg | 52–68 kcal/kg |
| Percent Resting Energy Expenditure | Not applicable | Not applicable | 100% REE | 130% REE | 150% REE |

Molecular Genetics and Metabolism Reports 25 (2020) 100685
studies of metformin, insulin, and testosterone in burned adults as well as oxandrolone, insulin, propranolol, and ketoanazole in burned children. Insulin, which has been a staple of treatment of metabolic crisis in children with MSUD for decades, was reported to increase both muscle protein breakdown and synthesis with a net increase in protein balance by 120% after treatment with 0.432 units/kg/h for 7 days in burned children. Ketoanazole showed no significant effect. Propranolol showed increase in net protein balance by 183% in burned children after treatment with 6.3 mg/kg/day divided in four doses per day for 2 weeks. Oxandrolone is a synthetic testosterone analogue with minimal virilizing effects which was shown to increase net protein balance by 107% after treatment with 0.1 mg/kg twice daily for 5 days [9].

Specific searches of the literature for studies of these drugs in MSUD revealed that metformin has a single study published [20]. This study demonstrated decrease in branched chain amino acid derived ketoacidosis and improvement in mitochondrial metabolic function in cultured patient fibroblasts and reports that the effects were preserved in a MSUD mouse model. There are no published clinical trials or case reports of metformin or any of the other reviewed pharmacotherapies in patients with MSUD.

Literature search for evidence supporting the use of growth hormone in children with MSUD revealed a single case report from 1968 which described MSUD metabolic crisis and states “The use of human growth hormone at such times has been considered. A fall in plasma amino acid levels has been observed following its administration but its value in clinical use is not yet established” [4]. More recently a physician William Nyhan published an article online for MSUD Family Support Group on the treatment of the acute crisis in MSUD. He described the use of insulin and glucose to promote anabolism and reverse catabolic states. He adds “More recently we have been using human growth hormone, a very powerful anabolic agent in this situation. At first, we only turned to growth hormone when amino acids plus insulin had not turned things around. More recently I have employed growth hormone earlier and have not needed to use insulin” [10].

Literature review of growth hormone in the treatment of other inherited disorders of metabolism revealed a few limited case series. D. Marsden et al. studied five patients with organic acidemias, two of which demonstrated decreased growth hormone secretion to stimulation challenge and reported increased protein tolerance of 20–60% with growth hormone treatment [5]. M. Al-Owain et al. report improved linear growth but no change in serum methylnalonic acid concentrations in two children with methylnalonic acidemia found to have growth hormone secretory deficiency [6]. C–H Kao et al. reports the use of growth hormone in four neonates with methylnalonic acidemia and observed weight gain and distinct improvement in skin erosions with indeterminant effect on serum proionyl carnitine levels [7]. H. Niiniokoski et al. treated four patients with lysinuric protein intolerance with growth hormone for 3–4.5 years and reported improvement in height standard deviation scores and no episodes of hyperammonemias [8].

4. Conclusion

This case report demonstrates positive response to the use growth hormone as a pharmacologic rescue in MSUD metabolic crisis refractory to standard therapy. Literature search suggests that more research is needed into protein anabolic pharmacology in inherited metabolic disease and that studies performed in pediatric burn patients may be relevant to this inquiry. Randomized controls trials of protein anabolic pharmacotherapy have been performed in the pediatric burn population as reviewed by Diaz et al. [9]. Promising interventions from these studies could be assessed for application in inherited metabolic disease to reverse catabolic processes and improve nitrogen balance. Although metabolic disease and severe burns are not typically considered together, these apparently disparate catabolic conditions may unlock clinical and biochemical insight to understand their pathophysiolog and improve metabolic care for both populations. The use of protein anabolic pharmacotherapy in inherited metabolic disease could reduce the need for dialysis and other invasive interventions in the management of acute metabolic crisis. Thus, protein anabolic pharmacotherapy with acceptable safety profiles and improvement in net protein balance should be considered as candidates for further study as adjuvants to standard of care management in inherited disorders of amino acid metabolism.

References

[1] K.A. Strauss, V.J. Carson, K. Solty, et al., Branched-chain α-ketoacid dehydrogenase deficiency (maple syrup urine disease): treatment, biomarkers, and outcomes, Mol. Genet. Metab. 129 (3) (2020) 193–206, https://doi.org/10.1016/j.ymgme.2020.01.006.

[2] D.M. Frazier, C. Allgeier, C. Homer, et al., Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach, Mol. Genet. Metab. 112 (3) (2014) 210–217, https://doi.org/10.1016/j.mgen.2014.05.006.

[3] R. Singh, F. Rohr, Nutrition Management Guidelines for MSUD. https://southatlenetics.org/npg/guidelines.php#10/MSUD, 2013.

[4] G.W. Hatcher, Maple syrup urine disease, J. R. Soc. Med. 61 (3) (1968) 287. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1902282/?page=1 (Accessed June 16, 2020).

[5] D. Marsden, B. Barshop, S. Capistranoestrada, et al., Anabolic effect of human growth hormone: management of inherited disorders of catabolic pathways, Biochem. Med. Metabolic Biol. 52 (2) (1994) 145–154, https://doi.org/10.1016/bmb.1994.1047.

[6] M. Al-Owain, C. Freehauf, L. Bernstein, M. Kappy, J. Thomas, Growth hormone deficiency associated with methylmalonic acidemia, J. Pediatr. Endocrinol. Metab. 17 (2) (2004) 239–243, https://doi.org/10.1515/jem.2004.17.2.239.

[7] C.H. Kao, M.Y. Liu, T.T. Liu, et al., Growth hormone therapy in neonatal patients with methylmalonic acidemia, J. Chin. Med. Assoc. 72 (9) (2009) 462–467, https://doi.org/10.1016/j.jtica.2009.07.008.

[8] H. Niiniokoski, R. Lapatto, M. Nunihiem, L. Tannek, O. Simell, K. Nanto-Salonen, Growth hormone treatment in children with lysinuric protein intolerance, JIMD Rep. 1 (2011) 43–47, https://doi.org/10.1002/j.8904.2011.15.

[9] E.C. Diaz, D.N. Herndon, C. Porter, L.S. Sidisosis, O.E. Suman, E. Borbesh, Effects of pharmacological interventions on muscle protein synthesis and breakdown in recovery from burn, Burns 41 (4) (2015) 649–657, https://doi.org/10.1016/j.burns.2014.10.010.

[10] W.L. Nyhan, Treatment of the Acute Crisis in Maple Syrup Urine Disease. http://msud-support.org/index.php/view--article&catid=38:volume-21-2&kid=265:tre-atment-of-the-acute-crisis-in-maple-syrup-urine-disease&option=com_content&fe mid=62, July 20, 2009.

[11] N.M. Mehta, H.E. Skillman, S.Y. Irving, J.A. Cos-Bu, S. Vermeijen, E.S. Farrington, L. McKeever, A.M. Hall, P.S. Goday, C. Braunschweig, Guidelines for the provision and assessment of nutrition support therapy in the pediatric critically ill patient: society of critical care medicine and American society of parenteral and enteral nutrition, JEN 41 (5) (2017) 707–742.

[12] M.R. Gorin (Ed.), The ASPEN Pediatric Nutrition Support Core Curriculum, 2015.

[13] Genotropin® Subcutaneous Injection, Somatropin (rDNA Origin) Subcutaneous Injection, Pharmacia & Upjohn Company, New York, NY, 2020.

[14] A. Grimberg, S.A. Divall, C. Polyuchakos, et al., Guidelines for growth hormone and insulin-like growth factor I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor I deficiency, Hormone Res. Pediatr. 86 (6) (2016) 361–397, https://doi.org/10.1159/000425250.

[15] J.G. Gardelis, T.D. Hatzis, L. Stamogiannou, A.A. Dona, A.D. Fotinou, S.P. Brestras, A.G. Constantopoulos, Activity of the growth hormone/insulin-like growth factor-I Axis in critically ill children, J. Pediatr. Endocrinol. Metab. 18 (4) (2005) 363–372, https://doi.org/10.1515/jpetm.2005.18.4.363.

[16] J. Bentham, J. Rodriguez-Arano, R. Buss, Acquired growth hormone resistance in patients with hypercatabolism, Horm. Res. 40 (1–3) (1993) 87–91, https://doi.org/10.1159/000183772.

[17] I.E. Elijah, L.K. Branski, C.C. Finnerty, D.N. Herndon, The GH/IGF-1 system in critical illness, Best Pract. Res. Clin. Endocrin. Metabol. 25 (5) (2011) 759–767, https://doi.org/10.1016/j.beem.2011.06.002.

[18] J. Takala, E. Roukoum, N. Wessber, M. Nielsen, D. Zandstra, Hindi C. Vundelinks, Increased mortality associated with growth hormone treatment in critically ill adults, N. Engl. J. Med. 349 (1991) 785–792, https://doi.org/10.1056/NEJM199909013411102.

[19] Critical evaluation of the safety of recombinant human growth hormone administration: statement from the growth hormone research society, Clin. Endocrinol. Metabol. 86 (5) (2001) 1868–1870, https://doi.org/10.1111/j.1365-2265.2001.t01-1-01720.x.

[20] D.S. Sonnet, M.N. O’Leary, M.A. Gutierrez, S.M. Nguyen, S. Matesen, Y. Hsu, K. P. Mitchell, A.J. Lopex, J. Vockley, B.K. Kennedy, A. Ramanathan, Metformin inhibits Branched Chain Amino Acid (BCAA) derived ketoacidosis and promotes metabolic homeostasis in MSUD, Sci. Rep. 6 (2016) 28775, https://doi.org/10.1038/srep28775.